Xilinx releases "Medical First" strategy to prioritize global medical customers in the fight against the epidemic

In such a global catastrophe, any effort by anyone will help defeat this "epidemic". Xilinx, Inc. (NASDAQ: XLNX), a global leader in adaptive computing and a core component provider for millions of medical devices around the world, announced:

Medical equipment applications are one of Xilinx's many medical applications. Xilinx's high-performance, flexible and adaptable FPGA, SoC and ACAP devices and solutions are the choice of almost all the world's top medical electronic equipment companies. In the current global battle against the new coronavirus, its outstanding medical customers are using Xilinx devices to support a variety of key equipment to fight the epidemic and save lives, such as ventilators, patient monitors, respirators and ICU beds, to treat diseases and save lives.

To fulfill this promise, Xilinx has set up a special cross-functional task force from operations and quality management teams to sales teams and channel partners, dedicated to providing the most efficient execution and communication channels for relevant customers, while also implementing various conveniences such as waiving expedited fees for some key needs. In addition, in order to respond promptly to the urgent supply needs of global medical users, Xilinx has set up a special mailbox.

In fact, as early as January, when the epidemic in China was at its peak, Xilinx had already given the green light to urgent orders from medical customers engaged in the fight against the epidemic. Starting from late January, when it supported Mindray in providing advanced monitoring system equipment to Wuhan, China, Xilinx's global operations and quality management team has been fully involved in the fight against the new coronavirus pneumonia. As of today, Xilinx has shipped a total of 55,000 devices by giving priority to Mindray and many world-renowned medical equipment and medical technology leaders in the United States, Europe and other regions, making positive contributions in helping medical customers develop and provide key technologies for testing and treating the new coronavirus and patients.